Lupus is an autoimmune disease where the body’s immune system becomes overly active and attacks normal, healthy tissue. The condition is chronic and ranges from mild to severe. Lupus can affect any part of the body – so it could affect the skin, joints or internal organs.
There are two main types of lupus. Systemic lupus erythematosus is the most common and can affect many parts of a person’s body, including the kidneys, heart, lungs, brain, blood and skin. Discoid lupus, on the other hand, only affects the skin.
Lupus UK estimates that around 50,000 people have lupus in the UK.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.